---
title: "Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286366040.md"
description: "Avalo Therapeutics, Inc. (AVTX) has highlighted new risk factors in its Form 10-Q, urging investors to consider these when evaluating the company's outlook. An external reviewer emphasizes that existing risks could significantly impact Avalo's operations and financial health. The average stock price target for AVTX is $46.89, indicating a potential upside of 136.22%."
datetime: "2026-05-14T06:03:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286366040.md)
  - [en](https://longbridge.com/en/news/286366040.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286366040.md)
---

# Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty

Avalo Therapeutics, Inc. (AVTX) has disclosed a new risk, in the Regulation category.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An external reviewer notes that Avalo Therapeutics, Inc. directs investors to carefully weigh the risk factors detailed in Part I of its Form 10‑Q when assessing the company’s outlook. This emphasis suggests that previously disclosed risks remain highly relevant and could materially affect Avalo’s operations, financial condition, and future prospects.

The average AVTX stock price target is $46.89, implying 136.22% upside potential.

To learn more about Avalo Therapeutics, Inc.’s risk factors, click here.

### Related Stocks

- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results](https://longbridge.com/en/news/286424446.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Avalo Therapeutics Q1 net loss widens on increased R&D spend](https://longbridge.com/en/news/286249018.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)